References relevant to drug promotion: 2002
This page lists all the 467 references relevant to drug promotion in the Healthy Skepticism library that were published in 2002 .
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL2623
Jureidini J, Mansfield PR.
Avoiding competing interests
BMJ 2002 Dec 27;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2897
Briggs DR.
The regulation of herbal medicines in Australia.
Toxicology 2002 Dec 27;181-182:565-70
Link to source with long URL
HSL2252
Thorat MA .
Grading the competing interests
BMJ 2002 Dec 20;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2352
Freudenheim M.
The Media Business: Advertising; Influencing Doctor's Orders
New York Times 2002 Dec 17
HSL2906
Ashcroft RE.
Conflicts of interest
BMJ 2002 Dec 17;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL2615
Kuczynski A.
Treating disease with a famous face.
New York Times 2002 Dec 15
http://www.nytimes.com/2002/12/15/fashion/15DISE.html
HSL2263
Smith R.
Making progress with competing interests.
BMJ 2002 Dec 14;325(7377):1375-6
http://bmj.com/cgi/reprint/325/7377/1375.pdf
HSL2890
Chaudhry S, Schroter S, Smith R, Morris J.
Does declaration of competing interests affect readers' perceptions? A randomised trial.
BMJ 2002 December 14;325:1391-1392
http://bmj.com/cgi/content/full/325/7377/1391
HSL2126
Collective action is good for you
University of Sussex Bulletin 2002 Dec 12
HSL2299
Petersen M.
Less return in marketing of medicines, a study says
New York Times 2002 Dec 12
http://www.nytimes.com/2002/12/12/business/12DRUG.html
HSL1222
Associated Press.
Ex-Lilly Workers Claim Corporate Backing
2002 Dec 11
HSL2124
The ASSOCIATED.
Ex - Lilly Workers Claim Corporate Backing
2002 Dec 11
HSL2342
Ex - Lilly Workers Claim Corporate Backing
THE ASSOCIATED PRESS 2002 Dec 11
HSL11332
Cohen GL.
Fiction: Off-label.
Neurology 2002 Dec 10;59(11):1818-20
http://www.neurology.org/cgi/content/full/59/11/1818
HSL2377
Marsa L.
Anti-anxiety drug market just keeps growing
Los Angeles Times 2002 Dec 9
Link to source with long URL
HSL2139
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4;:A1,
HSL2341
Warner J.
Misleading Drug Ads Persist
2002 Dec 4
HSL5919
Shilling C.
Culture, the 'sick role' and the consumption of health.
Br J Sociol 2002 Dec 01;53(4):621-38
Link to source with long URL
HSL2619
Klassen TP.
Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?
Arch Pediatr Adolesc Med 2002 Dec;156(12):1180-1
http://archpedi.ama-assn.org/cgi/content/full/156/12/1180
HSL2375
Miles MP, Munilla LS, Covin JG.
The Constant Gardener revisited: the effect of social blackmail on the marketing concept, innovation, and entrepreneurship.
J Bus Ethics 2002 Dec;41(3):287-95
Link to source with long URL
HSL1898
Tormala ZL, Petty RE.
What doesn't kill me makes me stronger: the effects of resisting persuasion on attitude certainty.
J Pers Soc Psychol 2002 Dec;83(6):1298-313
http://content.apa.org/journals/psp/83/6/1298
HSL2144
Chakrabarti A, Fleisher WP, Staley D, Calhoun L.
Interactions of staff and residents with pharmaceutical industry: a survey of psychiatric training program policies.
Ann R Coll Physicians Surg Can 2002 Dec;35(8)
HSL2163
Orme M, Frolich J, Vrhovac B; Education Sub-Committee of the European Association for Clinical Pharmacology and Therapeutics.
Towards a core curriculum in clinical pharmacology for undergraduate medical students in Europe.
Eur J Clin Pharmacol 2002 Dec;58(9):635-40
Link to source with long URL
HSL2165
Katz HP, Goldfinger SE, Fletcher SW.
Academia-industry collaboration in continuing medical education: description of two approaches.
J Contin Educ Health Prof 2002 Win;22(1):43-54
HSL2863
Hollis A.
The importance of being first: evidence from Canadian generic pharmaceuticals.
Health Econ 2002 Dec;11(8):723-34
Link to source with long URL
HSL2902
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Quality of global e-pharmacies: can we safeguard consumers?
Eur J Clin Pharmacol 2002 Dec;58(9):567-72
Link to source with long URL
HSL11136
Lampl C, Buzath A, Yazdi K, Sandor PS.
Ergot and triptan overuse in Austria--an evaluation of clinical data and cost.
Cephalalgia 2002 Dec;22(10):807-11
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1468-2982.2002.00442.x
HSL11315
Avouac B.
Prescribing outside the limits of marketing authorizations and reimbursement by the French universal health insurance system.
Joint Bone Spine 2002 Dec;69(6):534-7
Link to source with long URL
HSL11319
Carroll NV.
How effectively do managed care organizations influence prescribing and dispensing decisions?
Am J Manag Care 2002 Dec;8(12):1041-54
http://www.ajmc.com/Article.cfm?ID=113&CFID=8980495&CFTOKEN=81996035
HSL11321
Dargan P, Jones A.
Paracetamol: balancing risk against benefit.
QJM 2002 Dec;95(12):831-2
http://qjmed.oxfordjournals.org/cgi/content/full/95/12/831
HSL2250
Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J.
[A case report of mania precipitated by use of DHEA].
Encephale. 2002 Nov-Dec 28;6:563-6
Link to source with long URL
HSL2613
Labarre R.
Doctors and Industry
The New York Times 2002 Nov 28
http://www.nytimes.com/2002/11/28/opinion/L28DRUG.html
HSL1261
PR Newswire Association LLC
Pharmaceutical giants over-invest in promotion
2002 Nov 27
http://www.bioportfolio.com/news/report_1.htm
HSL2340
Zuckerman D.
Hype in Health Reporting
AlterNet 2002 Nov 25
HSL2876
Dukes MN.
Accountability of the pharmaceutical industry.
Lancet 2002 Nov 23;360(9346):1682-4
http://linkinghub.elsevier.com/retrieve/pii/S0140673602115996
HSL2618
Klausner JD, Kim A, Kent C.
Are HIV drug advertisements contributing to increases in risk behavior among men in San Francisco, 2001?
AIDS 2002 Nov 22;16(17):2349-50
Link to source with long URL
HSL4279
Petersen , M .
Madison Ave. plays growing role in drug research
New York Times 2002 Nov 22
http://www.nytimes.com/2002/11/22/business/22DRUG.html
HSL2248
Vitry AI, Hurley E.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177(10):572-3
http://www.mja.com.au/public/issues/177_10_181102/vitry_181102.html
HSL4281
Gazarian M, Kaye KI.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Nov 18;177(10):572-3
HSL5999
Murphy S.
Gifts seen effective by drug company reps
Boston Globe 2002 Nov 17
HSL2866
Henry D, Lexchin J.
The pharmaceutical industry as a medicines provider.
Lancet 2002 Nov 16;360(9345):1590-5
Link to source with long URL
HSL4283
Smith R.
New BMJ policy on economic evaluations.
BMJ 2002 Nov 16;325(7373):1124
Link to source with long URL
HSL2908
Abraham J.
The pharmaceutical industry as a political player.
Lancet 2002 Nov 9;360(9344):1498-502
Link to source with long URL
HSL2353
Viva Viagra
2002 Nov 2
HSL2854
James A.
Medicines, society, and industry.
Lancet 2002 Nov 2;360(9343):1346
Link to source with long URL
HSL2886
Collier J, Iheanacho I.
The pharmaceutical industry as an informant.
Lancet 2002 Nov 2;360(9343):1405-9
Link to source with long URL
HSL12237
Collier J, Iheanacho I.
The pharmaceutical industry as an informant.
Lancet 2002 Nov 2;360(9343):1405-9
http://linkinghub.elsevier.com/retrieve/pii/S0140673602113948
HSL2911
Drug companies offer DM programs for MS patients.
Dis Manag Advis. 2002 Nov 01;8(11):165-8, 161
Link to source with long URL
HSL556
Brodie M, Levitt L.
Drug advertising: the right or wrong prescription for our ailments?
Nat Rev Drug Discov 2002 Nov;1(11):916-20
Link to source with long URL
HSL1485
Wirth M, Scherer D.
Patient's perceptions of doctors' relationships with pharmaceutical companies
Healthy Skepticism International News 2002 Nov;20(11)
www.healthyskepticism.org
HSL2295
Rakatansky H.
Review article: gastroenterology and the pharmaceutical industry.
Aliment Pharmacol Ther 2002 Nov;16(11):1859-66
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2036.2002.01362.x
HSL2871
Glasgow C, Schommer JC, Gupta K, Pierson K.
Promotion of prescription drugs to consumers: case study results.
J Manag Care Pharm 2002 Nov-Dec;8(6):512-8
Link to source with long URL
HSL2899
Boltri JM, Gordon ER, Vogel RL.
Effect of antihypertensive samples on physician prescribing patterns.
Fam Med 2002 Nov-Dec;34(10):729-31
Link to source with long URL
HSL11284
Macia MA, Carvajal A, del Pozo JG, Vera E, del Pino A.
Hepatotoxicity associated with nimesulide: data from the Spanish Pharmacovigilance System.
Clin Pharmacol Ther 2002 Nov;72(5):596-7
HSL11325
Biswas PN, Wilton LV, Shakir SW.
The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
J Hum Hypertens 2002 Nov;16(11):795-803
http://www.nature.com/jhh/journal/v16/n11/abs/1001490a.html
HSL11326
Shiffman S, Gorsline J, Gorodetzky CW.
Efficacy of over-the-counter nicotine patch.
Nicotine Tob Res 2002 Nov;4(4):477-83
Link to source with long URL
HSL11331
Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G.
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Eur J Clin Pharmacol 2002 Nov;58(8):495-500
http://www.springerlink.com/content/c52uy58a4h0jd0k2/
HSL2328
Company News; Glaxo Seeks F.D.A. Approval Of Depression Treatment
2002 Oct 30
HSL2884
Corbett J.
Drug pushers - the campaign for Glivec funding
New Zealand Herald 2002 Oct 26
http://www.nzherald.co.nz/storydisplay.cfm?storyID=3001076
HSL2288
Schulman KA, Seils DM, Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM.
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.
N Engl J Med 2002 Oct 24;347(17):1335-41
http://content.nejm.org/cgi/content/abstract/347/17/1335
HSL2334
O'Meara K P
Medical Research To Die For
Insight magazine 2002 Oct 15
HSL2327
Seglin J.
Just Saying No to Gifts From Drug Makers
2002 Oct 8
HSL2257
Sweet M.
Conference promotion in the media: serving whose interests?
Med J Aust 2002 Oct 7;177(7):341-2
http://www.mja.com.au/public/issues/177_07_071002/swe10463_fm.html
HSL2324
Moore K.
Drug companies push pills to doctors
Morning Journal Writers 2002 Oct 7
HSL2339
Croasdale M.
CME providers gear up to comply with PhRMA code: Eager to follow new guidelines separating drug promotions from continuing medical education, CME presenters' questions outpace answers at a meeting of drug industry and education leaders.
AMNews 2002 Oct 7
HSL1420
Braithwaite J.
Restorative Justice and Responsive Regulation
Oxford: Oxford University Press; 2002
http://www.oup.co.uk/isbn/0-19-515839-3
HSL2683
Cassels A.
Consumer drug advertising leads to MD backlash in Holland.
CMAJ 2002 Oct 1;167(7):793
http://www.cmaj.ca/cgi/content/full/167/7/793
HSL5863
Coast J, Smith R, Karcher AM, Wilton P, Millar M.
Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance?
Health Econ 2002 Oct 01;11(7):637-47
http://www3.interscience.wiley.com/cgi-bin/abstract/93521364/ABSTRACT
HSL2568
Maitland I.
Priceless goods: how should life-saving drugs be priced?
Bus Ethics Q 2002 Oct;12(4):451-80
Link to source with long URL
HSL1662
Jureidini J.
Does the International Consensus Statement on ADHD leave room for healthy scepticism?
Eur Child Adolesc Psychiatry 2002 Oct;11(5):240
HSL2217
Brotons C, Moral I, Ribera A, Cascant P, Iglesias M, Permanyer-Miralda G, Ferreira Gonzalez I, Soler-Soler J.
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention.]
Rev Esp Cardiol 2002 Oct;55(10):1042-51
Link to source with long URL
HSL2331
Burson-Marsteller's Task Force
Media Watch. 2002 Sep 30
HSL2856
Transparency International.
Slovak judge, German pharmacologist and Brazilian campaigner win anti-corruption award
2002 Sep 30
Link to source with long URL
HSL2442
Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, Fireman B.
Discontinuation of use and switching of antidepressants: influence of patient-physician communication.
JAMA 2002 Sep 18;288(11):1403-9
http://jama.ama-assn.org/cgi/content/full/288/11/1403
HSL1980
Shear NH.
Principles of influence.
CMAJ 2002 Sep 17;167(6):628
http://www.cmaj.ca/cgi/content/full/167/6/628
HSL2330
Adams C.
Firms Pressure FDA to Relax Rules on Commercial Speech
THE WALL STREET JOURNAL 2002 Sep 17
HSL2116
Salleh A.
Prescription drug ads under attack
ABC Science Online 2002 Sep 16
HSL2305
Newby DA, Henry DA.
Drug advertising: truths, half-truths and few statistics.
Med J Aust 2002 Sep 16;177(6):285-6
http://www.mja.com.au/public/issues/177_06_160902/new10443_fm.html
HSL2610
Loke TW, Koh FC, Ward JE.
Pharmaceutical advertisement claims in Australian medical publications.
Med J Aust 2002 Sep 16;177(6):291-3
http://www.mja.com.au/public/issues/177_06_160902/lok10004_fm.html
HSL2309
Moynihan R.
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
BMJ 2002 Sep 14;325(7364):592-5
http://bmj.bmjjournals.com/cgi/content/full/325/7364/592
HSL2118
Burson-Marsteller's Task Force
Media Watch. Australian Broadcasting Commission 2002 Sep 13
HSL5967
Accreditation Council for Graduate Medical Education
Principles to Guide the Relationship between Graduate Medical Education and Industry
: Accreditation Council for Graduate Medical Education; 2002 Sep 10
http://www.acgme.org/acWebsite/positionPapers/pp_GMEGuide.pdf
HSL2351
Wysong P.
Time with drug reps affects prescribing: study
The Medical Post. 2002 Sep 8
HSL2889
Clifford TJ, Barrowman NJ, Moher D.
Funding source, trial outcome and reporting quality: are they related? Results of a pilot study
BMC Health Serv Res 2002 September 4;2(1):18
http://www.biomedcentral.com/1472-6963/2/18
HSL5835
Casebeer L, Allison J, Spettell CM.
Designing tailored Web-based instruction to improve practicing physicians' chlamydial screening rates.
Acad Med 2002 Sep 01;77(9):929
http://www.jmir.org/ms/login.php
HSL8302
McAllister JC 3rd.
Providing for the pharmaceutically indigent.
Am J Health Syst Pharm 2002 Sep 1;59(17):1678-9
http://www.ajhp.org/cgi/reprint/59/17/1678
HSL9591
Cox TP.
Forging Alliances: Advocacy Partners
Pharmaceutical Executive 2002 Sep 1
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=29974
HSL2448
Fugh-Berman A, Pearson C.
The overselling of hormone replacement therapy.
Pharmacotherapy 2002 Sep;22(9):1205-8
HSL2499
Caamano F, Figueiras A , Gestal-Otero JJ.
Influence of commercial information on prescription quantity in primary care.
Eur J Public Health 2002 Sep;12(3):187-91
Link to source with long URL
HSL1486
Wazana A, Primeau F.
Ethical considerations in the relationship between physicians and the pharmaceutical industry.
Psychiatr Clin North Am 2002 Sep;25(3):647-63,
Link to source with long URL
HSL1893
Sagarin BJ, Cialdini RB, Rice WE, Serna SB.
Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion.
J Pers Soc Psychol 2002 Sep;83(3):526-41
http://content.apa.org/journals/psp/83/3/526
HSL2245
Wall LL, Brown D.
Pharmaceutical sales representatives and the doctor/patient relationship.
Obstet Gynecol 2002 Sep;100(3):594-9
http://www.greenjournal.org/cgi/content/full/100/3/594
HSL2261
Stewart KA, Neumann PJ.
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Value Health 2002 Sep-Oct;5(5):389-96
Link to source with long URL
HSL2290
Safer DJ.
Design and reporting modifications in industry-sponsored comparative psychopharmacology trials.
J Nerv Ment Dis 2002 Sep;190(9):583-92
Link to source with long URL
HSL2306
Neumann PJ, Zivin Bambauer K, Ramakrishnan V, Stewart KA, Bell CM.
Economic messages in prescription drug advertisements in medical journals.
Med Care 2002 Sep;40(9):840-5
Link to source with long URL
HSL2311
Motola G, Mazzeo F, Rinaldi B, Capuano A, Rossi S, Russo F, Vitelli MR, Rossi F, Filippelli A.
Self-prescribed laxative use: a drug-utilization review.
Adv Ther 2002 Sep-Oct;19(5):203-8
Link to source with long URL
HSL2883
Cox ER, Henderson RR.
Prescription use behavior among medicare beneficiaries with capped prescription benefits.
J Manag Care Pharm 2002 Sep-Oct;8(5):360-4
Link to source with long URL
HSL8285
De Las Cuevas C, Sanz EJ, De La Fuente JA.
Variations in antidepressant prescribing practice: clinical need or market influences?
Pharmacoepidemiol Drug Saf 2002 Sep;11(6):515-22
HSL11292
Bachert C, El-Akkad T.
Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis.
Ann Allergy Asthma Immunol 2002 Sep;89(3):292-7
HSL13226
Le TV.
Money talks
Reportage 2002 Sep
http://www.reportage.uts.edu.au/stories/2002/media/pr2k9.html
HSL2115
Company News; Glaxo Seeks F.D.A. Approval Of Depression Treatment
2002 Aug 30
HSL2858
Health ACTION.
European Parliament soundly rejects move towards direct-to-consumer advertising. HAI Europe applauds Parliament's decision to protect public health, not industry's interests
2002 Aug 24
http://www.haiweb.org/campaign/DTCA/pressreleaseEUrejectsDTCA.html
HSL2439
Sackett DL.
The arrogance of preventive medicine.
CMAJ 2002 Aug 20;167(4):363-4
http://www.cmaj.ca/cgi/content/full/167/4/363
HSL2684
Sheldon T.
Dutch GPs call for ban on Novartis products.
BMJ 2002 Aug 17;325(7360):355
http://bmj.bmjjournals.com/cgi/content/full/325/7360/355
HSL2113
Philip Morris Muzzled Marketing of Cessation Products
2002 Aug 15
HSL2326
Philip Morris Muzzled Marketing of Cessation Products
2002 Aug 15
HSL2258
Sweet M.
Australian media raises alarm over meningitis
BMJ 2002 Aug 14;325:604
http://bmj.com/cgi/content/full/325/7364/604
HSL2287
Shamasunder B, Bero L.
Financial ties and conflicts of interest between pharmaceutical and tobacco companies.
JAMA 2002 Aug 14;288(6):738-44
http://jama.ama-assn.org/cgi/content/full/288/6/738
HSL2873
Fontanarosa PB, DeAngelis CD.
The importance of the journal embargo.
JAMA 2002 Aug 14;288(6):748-50
http://jama.ama-assn.org/cgi/content/full/288/6/748
HSL2112
Petersen M.
Heartfelt Advice, Hefty Fees
New York Times 2002 Aug 11
HSL164
Gerstel J.
Who benefits when doctors endorse drugs?
The Tortonto Star 2002 Aug 9
HSL2121
Croasdale M.
CME providers gear up to comply with PhRMA code: Eager to follow new guidelines separating drug promotions from continuing medical education, CME presenters' questions outpace answers at a meeting of drug industry and education leaders.
AMNews 2002 Aug 7
HSL2620
Kjaergard LL, Als-Nielsen B.
Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ.
BMJ 2002 Aug 3;325(7358):249
http://bmj.com/cgi/content/full/325/7358/249
HSL2216
Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, Dubois S, Russo R.
Assessing the quality of drug detailing.
J Clin Epidemiol 2002 Aug;55(8):825-32
HSL2912
[No authors listed].
Is Yasmin a 'truly different' drug?
Drug Ther Bull 2002 Aug;40(8):57-9
Link to source with long URL
HSL2074
Williams A.
The mental health industry
2002 Jul 16
HSL13992
Antonuccio DO, Burns DD, Danton WG.
Antidepressants: A triumph of marketing over science?
Prevention & Treatment. 2002 Jul 15;5(1):Item 25
http://content.apa.org/journals/pre/5/1/25
HSL2888
CMAJ
The invisible hand of the marketing department.
CMAJ 2002 Jul 9;167(1):5
http://www.cmaj.ca/cgi/content/full/167/1/5
HSL2070
Doctors under fire over drug company payments
2002 Jul 5
HSL2291
Rosack J.
Drug industry responds to complaints about marketing
Psychiatric News 2002 Jul 5;37(13):1
http://pn.psychiatryonline.org/cgi/content/full/37/13/1
HSL2676
Lehner JP, Meyer F, Juillet Y.
[Communication and transparency concerning risk-benefit analysis in public health: the example of medication]
Therapie. 2001 Jul-Aug;56(4):335-9 2002 Jul-Aug 01;56(4):335-9
HSL2910
Health plans keeping drug cost increases in check with programs that promote generics.
Capitation Manag Rep. 2002 July 01;9(7):101-3
Link to source with long URL
HSL5867
Doolan DF, Bates DW.
Computerized physician order entry systems in hospitals: mandates and incentives.
Health Aff (Millwood) 2002 Jul-Aug 01;21(4):180-8
http://content.healthaffairs.org/cgi/reprint/21/4/180
HSL2254
Theroux R.
Bypassing the middleman: a grounded theory of women's self-care for vaginal symptoms.
Health Care Women Int 2002 Jul-Aug;23(5):417-31
Link to source with long URL
HSL2296
Quinn RJ, O'Neill C.
Attitudes of general practitioners to their interactions with pharmaceutical companies: a qualitative study.
Ir Med J 2002 Jul-Aug;95(7):199-202
Link to source with long URL
HSL2617
Klein JE, Fleischman AR.
The private practicing physician-investigator: ethical implications of clinical research in the office setting.
Hastings Cent Rep 2002 Jul-Aug;32(4):22-6
Link to source with long URL
HSL2885
Coolidge MP.
Drug samples: friend or foe?
J Drugs Dermatol 2002 Jul;1(1):49-52
Link to source with long URL
HSL2904
Bennett J, Collins J.
The relationship between physicians and the biomedical industries: advice from the Royal College of Physicians.
Clin Med 2002 Jul-Aug;2(4):320-2
Link to source with long URL
HSL2859
Hoye S, Hjortdahl P.
New wonder pill!--what do Norwegian newspapers write
2002 Jun 30;122(17):1671-6 2002 June 30;122(17):1671-6
Link to source with long URL
HSL1982
Redelmeier DA, Cialdini RB.
Problems for clinical judgement: 5. Principles of influence in medical practice
CMAJ 2002 Jun 25;166(13):1680-4
http://www.cmaj.ca/cgi/content/full/166/13/1680
HSL2612
Leenen FH.
Conflicts of interest and libel action.
N Engl J Med 2002 Jun 13;346(24):1919-20
HSL2877
Drazen JM, Curfman GD.
Financial associations of authors.
N Engl J Med 2002 Jun 13;346(24):1901-2
http://content.nejm.org/cgi/content/full/346/24/1901
HSL2880
Detsky A[AU].
Dr Detsky replies
NEJM 2002 Jun 13;346(24):1920
HSL2069
Hawkes N.
How to spot a 'misleading' health story
2002 Jun 5
HSL259
Stevenson K.
Health Forum: Out of the game: A frustrated psychiatrist abandons her practice to get out from under 'evaluating and medicating'
Post Gazette (Pittsburgh) 2002 Jun 4
HSL5944
Orlowski JP, Christensen JA.
The potentially coercive nature of some clinical research trial acronyms.
Chest 2002 Jun 01;121(6):2023-8
http://www.chestjournal.org/cgi/content/full/121/6/2023
HSL2292
Ripamonti C, Bianchi M.
The use of methadone for cancer pain.
Hematol Oncol Clin North Am 2002 Jun;16(3):543-55
HSL2298
Pinkus RL.
From Lydia Pinkham to Bob Dole: what the changing face of direct-to-consumer drug advertising reveals about the professionalism of medicine.
Kennedy Inst Ethics J 2002 Jun;12(2):141-58
Link to source with long URL
HSL11094
Tackling antibiotic waste.
Prescrire Int 2002 Jun;11(59):93
HSL11095
Missing data.
Prescrire Int 2002 Jun;11(59):92
HSL2067
Vedantam S.
Industry Role in Medical Meeting Decried
Washington Post Staff Writer 2002 May 26
HSL2891
Charatan F.
Doctor sues company over unethical marketing.
BMJ 2002 May 25;324(7348):1234
http://bmj.com/cgi/content/full/324/7348/1234/b
HSL2066
Petersen M.
Suit Says Company Promoted Drug in Exam Rooms
2002 May 15
HSL2065
Health Fact Sheet 1 – Securing the future of the Pharmaceutical Benefits Scheme
2002 May 14
HSL2155
Romano M.
Student rally Med school attendees write ethics code on drug firms.
Mod Healthc 2002 May 13;32(19):24,
HSL4163
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH.
Timing of new black box warnings and withdrawals for prescription medications.
JAMA 2002 May 1;287(17):2215-20
http://jama.ama-assn.org/cgi/content/full/287/17/2215
HSL6211
Herlihyj , Gandy , J
Causation and explanation
The Psychologist 2002 May 1;15(5):248-251
HSL1896
Petty RE, Brinol P, Tormala ZL.
Thought confidence as a determinant of persuasion: the self-validation hypothesis.
J Pers Soc Psychol 2002 May;82(5):722-41
http://content.apa.org/journals/psp/82/5/722
HSL2303
Panush RS.
Not for sale, not even for rent: just say no. Thoughts about the American College of Rheumatology adopting a code of ethics.
J Rheumatol 2002 May;29(5):1049-57
http://www.jrheum.com/subscribers/02/05/1049.html
HSL5830
Beckwith H.
Selling the Invisible : A Field Guide to Modern Marketing
New York: Texere; 2002
HSL2063
Mallaby S.
Arthur Andersens of Medicine
Washington Post 2002 Apr 28
HSL2064
Mallaby S.
Arthur Andersens of Medicine
Washington Post 2002 Apr 28
HSL2068
Drugmarketing in the 21st Century
2002 Apr 27
HSL2062
Medicines in Europe Forum, Medicines policy projects: A threat to consumers and patients
e-drug 2002 Apr 26
http://www.essentialdrugs.org/edrug/archive/200204/msg00108.php
HSL2297
Pope John Paul II.
The profit motive behind too much medical research.
Origins 2002 Apr 25;31(45):754-5
Nil
HSL2060
Hensley S.
New Rules Will Push Drug Firms To New Tactics in Wooing Doctors
THE WALL STREET JOURNAL 2002 Apr 23
HSL2061
Gina KOLATA.
In Public Health, Definitive Data Can Be Elusive
New York Times 2002 Apr 23
HSL2444
Young JM, Glasziou P, Ward JE.
General practitioners' self ratings of skills in evidence based medicine: validation study.
BMJ 2002 Apr 20;324(7343):950-1
http://bmj.bmjjournals.com/cgi/content/full/324/7343/950
HSL2059
Brubaker B.
Drug Industry Adopts Guidelines on Giveaways to Doctors
Washington Post 2002 Apr 20
HSL2882
Dal-Pizzol F.
Drug advertisements in less-developed countries.
Lancet 2002 Apr 20;359(9315):1439-40
http://linkinghub.elsevier.com/retrieve/pii/S0140673602083836
HSL2054
Grady D.
Scientists Question Hormone Therapies for Menopause Ills
New York Times 2002 Apr 19
HSL2055
Pollack A
Despite Billions for Discoveries, Pipeline of Drugs Is Far From Full
The New York Times 2002 Apr 19
HSL2056
Agovino T.
Drug industry tightens guidelines on marketing to doctors
AP Business Writer 2002 Apr 19
HSL2057
Clarke T.
Drugmakers Plan New Rules to Cut Perks for Doctors
Reuters 2002 Apr 19
HSL2058
Hensley S.
Drug industry curbs 'dine and dash' marketing
THE WALL STREET JOURNAL 2002 Apr 19
HSL2052
Parker-pope T.
Latest Craze in Coupon-Clipping: Free Trials for Prescription Drugs
Wall Street Journal 2002 Apr 16
HSL2053
New Findings on Physicians' Views of Doctors and Prescription Drugs
The Henry J. Kaiser Family Foundation 2002 Apr 16
HSL2051
Jopson D.
Vaccine for Aborigines spurned by drug makers
Sydney Morning Herald 2002 Apr 15
HSL2452
Moynihan R, Heath I, Henry D.
Selling sickness: the pharmaceutical industry and disease mongering.
BMJ 2002 Apr 13;324(7342):886-91
http://bmj.bmjjournals.com/cgi/content/full/324/7342/886
HSL2373
Mintzes B.
For and against: Direct to consumer advertising is medicalising normal human experience: For.
BMJ 2002 Apr 13;324(7342):908-9
http://bmj.bmjjournals.com/cgi/content/full/324/7342/908
HSL2049
Robotham J.
Illness exaggerated as companies strive to sell more drugs
Sydney Morning Herald 2002 Apr 13
HSL2050
Metherall M.
Drug deals
Sydney Morning Herald 2002 Apr 13
HSL2310
Moynihan R.
Drug firms hype disease as sales ploy, industry chief claims.
BMJ 2002 Apr 13;324(7342):867
http://bmj.bmjjournals.com/cgi/content/full/324/7342/867
HSL2898
Bonaccorso S, Sturchio J.
Direct to consumer advertising is medicalising normal human experience: Against
BMJ 2002 Apr 13;324(7342):910-911
http://bmj.com/cgi/content/full/324/7342/910
HSL8393
Bonaccorso SN, Sturchio JL.
For and against: Direct to consumer advertising is medicalising normal human experience: Against.
BMJ 2002 Apr 13;324(7342):910-1
Link to source with long URL
HSL8394
Mintzes B.
For and against: Direct to consumer advertising is medicalising normal human experience: For.
BMJ 2002 Apr 13;324(7342):908-9
http://www.bmj.com/cgi/content/full/324/7342/908
HSL2047
O'Malley N.
Ad agencies liable if they mislead
Sydney Morning Herald 2002 Apr 12
HSL2048
Denoon D.
Are Drug Companies Making Us Sick?
WebMD Medical News 2002 Apr 12
HSL2044
Burne J.
The drug pushers
Guardian 2002 Apr 11
HSL2045
Winslow R.
Black Doctors See Drug Ads As Beneficial for Minorities
THE WALL STREET JOURNAL 2002 Apr 11
HSL2046
Petersen M.
Methods Used for Marketing Arthritis Drug Are Under Fire
New York Times 2002 Apr 11
HSL2043
Metherell M.
Budget to force up drug prices
Sydney Morning Herald 2002 Apr 10
HSL12345
Kolata G.
Test Proves Fruitless, Fueling New Debate on Cancer Screening
New York Times 2002 Apr 9
Link to source with long URL
HSL2042
Giombetti R.
Suicide Science
www.counterpunch.org 2002 Apr 8
HSL2875
The Editor
Just how tainted has medicine become.
Lancet 2002 April 6;359(9313):1167
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081989
HSL5961
Just how tainted has medicine become?
Lancet 2002 Apr 6;359(9313):1167
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081989
HSL2040
Robotham J.
Big business, bad medicine cloud our epidemic of the blues
The Sydney Morning Herald 2002 Apr 3
HSL2041
Keon J.
Prescription medicine: "Think of the needs of tax payers before those of the multinationals"
Canadian Drug Manufacturers Association 2002 Apr 3
HSL2893
Cassels A.
Push for consumer drug ads gets cool reception in Europe.
CMAJ 2002 Apr 2;166(7):946
http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=11949998
HSL2039
Toner R.
Rising Drug Costs a Powerful Issue for National and State Politicians
New York Times 2002 Apr 1
HSL4282
Edmonds JP, Day RO, Bertouch JV.
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors.
Med J Aust 2002 Apr 1;176(7):332-4
http://www.mja.com.au/public/issues/176_07_010402/edm10003_fm.html
HSL6415
Toop L, Richards D.
DTCA in New Zealand: the challenge of finding an acceptable balance
Br J Gen Pract. 2002 Apr 1;52(477):341
HSL2374
Miller FG, Shorr AF.
Ethical assessment of industry-sponsored clinical trials: a case analysis.
Chest 2002 Apr;121(4):1337-42
http://www.chestjournal.org/cgi/content/full/121/4/1337
HSL2249
Viale PH.
Direct-to-consumer advertising of prescription medications: implications for patients with cancer.
Oncol Nurs Forum 2002 Apr;29(3):505-13
Link to source with long URL
HSL2909
[No authors listed].
Roche turns to DM to boost patient compliance with its weight loss drug.
Dis Manag Advis 2002 Apr;8(4):51-4,
Link to source with long URL
HSL8020
Liebman M.
Awakening the Silent Osteoporosis Market
Medical Marketiing and Media 2002 Apr
http://www.mmm-online.com/content/fileadmin/files/features/2002/Osteo.pdf
HSL2036
Metherell M.
Drug makers told to justify their sky-high prices
Sydney Morning Herald 2002 Mar 30
HSL2037
Gordon C.
TV drug ads are tough to swallow
The Ottawa Citizen 2002 Mar 30
HSL2032
Top-Selling Drugs Push Drug Spending Up 17.1% in 2001
2002 Mar 29
HSL2033
Freudenheim M.
Drug Spending Rises Sharply At Pharmacies and by Mail
The New York Times 2002 Mar 29
Link to source with long URL
HSL2034
Connolly C.
Medication Spending Continues Steady Rise
Washington Post 2002 Mar 29
HSL2031
O'Connell V.
Drug Marketers' Ads Penetrate Text of Online Medical Studies
Wall Street Journal 2002 Mar 28
HSL2030
Arno P.
Paying Twice for the Same Drugs
Washington Post 2002 Mar 27
HSL2028
Walsh M.
When a Buyer for Hospitals Has a Stake in Drugs It Buys
New York Times 2002 Mar 26
HSL2027
Zuckerman D.
Is Drug Safety Being Enron'd?
redflagsweekly 2002 Mar 25
HSL114
Lenzer J.
Alteplase for stroke: money and optimistic claims buttress the “brain attack“ campaign.
BMJ 2002 Mar 23;324:723-726
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723
HSL2026
McGregor .
Ban on drug ads to stay: McLellan
The Ottawa Citizen 2002 Mar 23
HSL2304
Orellana C.
German doctors' links with drug firm investigated.
Lancet 2002 Mar 23;359(9311):1039
http://linkinghub.elsevier.com/retrieve/pii/S0140673602081126
HSL2025
The menace of fake drugs in Nigeria
2002 Mar 22
HSL2024
McNeil D.
New List of Safe AIDS Drugs, Despite Industry Lobby
New York Times 2002 Mar 21
HSL2023
Health-literate patients-an asset to society
European Federation of Pharmaceutical Industries and Associations 2002 Mar 19
HSL2021
Pallarito K.
Lawmakers pass resolution to press US Congress on lower drug prices
Reuters Health 2002 Mar 15
HSL2022
Fuhrmans V.
European Drug Makers May Utilize More Aggressive Marketing Tactics
The Wall Street Journal 2002 Mar 15
HSL8395
Young D.
FTC-Lilly settlement sheds light on e-mail privacy with patients.
Am J Health Syst Pharm 2002 Mar 15;59(6):509
http://www.ajhp.org/
HSL8616
Williams C.
Aspirin Can't Cure Bayer's Aches
Los Angeles Times 2002 Mar 15:C4
Link to source with long URL
HSL2018
Adams C.
FDA Is Inundated Trying To Assess Drug Ad Pitches
THE WALL STREET JOURNAL 2002 Mar 14
HSL2019
Hensley S.
More Than Ads, Drug Makers Rely on Sales Representatives
THE WALL STREET JOURNAL 2002 Mar 14
HSL2020
Petersen M.
Whistle-Blower Says Marketers Broke the Rules to Push a Drug
New York Times 2002 Mar 14
HSL2009
Gardiner H.
Drug Makers Offer Consumers Coupons for Free Prescriptions
THE WALL STREET JOURNAL 2002 Mar 13
HSL2010
Burton T.
Backlash Rises Against Flashy Ads For Prescription Pharmaceuticals
THE WALL STREET JOURNAL 2002 Mar 13
HSL2011
O'Connell V.
Ad Agencies Begin to Participate In Development of New Drugs
The wall street journal 2002 Mar 13
HSL2016
German Public Prosecutor investigates doctors who have received gifts from GSK
Trouw newspaper 2002 Mar 13
HSL2007
Cleaver H.
Bribery of German Docs by Drug Companies
2002 Mar 11
HSL2004
Metherell M.
Patients face drug rations
Sydney Morning Herald 2002 Mar 9
HSL2006
Craig T
Community Leaders Decry Lobby Firm's Fax
Baltimore Sun 2002 Mar 9
HSL2002
Moynihan R.
ACA urges cut to $4bn drug bill
Australian Financial Review 2002 Mar 8
HSL2003
Petersen M
TV Ads Spur a Rise in Prescription Drug Sales
New York Times 2002 Mar 8
HSL2001
Italy suspends sales of sibutramine over adverse events
Reuters Health 2002 Mar 7
HSL2000
Avantago introduces mobile application built specifically for pharmaceutical sales
HAYWARD 2002 Mar 4
HSL2005
Ottawa must protect public from drug ads
The Toronto Star 2002 Mar 3
HSL1999
Treating depression
2002 Mar 1
HSL2892
Castaigne A.
[Role of drugs in therapeutic strategies].
Rev Prat. 2002 March 1;52(5):491-6
Link to source with long URL
HSL8439
Young D.
Drug industry sues states over prescription programs for low-income residents.
Am J Health Syst Pharm 2002 Mar 1;59(5):408
http://www.ajhp.org/cgi/pmidlookup?view=reprint&pmid=11887405
HSL2437
Hall KH.
Reviewing intuitive decision-making and uncertainty: the implications for medical education.
Med Educ 2002 Mar;36(3):216-24
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1365-2923.2002.01140.x
HSL2008
How does pharmaceutical marketing influence doctors' prescribing behaviour?
2002 Mar
HSL2015
Jung P.
No Free Lunch
Health Affairs 2002 Mar
HSL2038
McKinnell H.
Towards a sustainable solution - funding innovative medicines
Pharmapolicy News 2002 Mar
HSL2262
Spilker B.
The benefits and risks of a pack of M&Ms: A pharmaceutical spokesman answers his industry's critics
Health Affairs 2002 3-4;21(2):243-244
Link to source with long URL
HSL2294
Rao SK.
Pharmaceutical marketing in a new age, Effective campaigns still need to focus on what customers want.
Mark Health Serv 2002 Spring;22(1):6-12
HSL2614
Kunst H, Khan KS.
Quality of web-based medical information on stable COPD: comparison of non-commercial and commercial websites.
Health Info Libr J 2002 Mar;19(1):42-8
http://www.blackwell-synergy.com/doi/abs/10.1046/j.0265-6647.2001.00363.x
HSL2879
D'Mello B.
Transnational pharmaceutical corporations and neo-liberal business ethics in India.
J Bus Ethics 2002 Mar;36(1-2):165-85
Link to source with long URL
HSL2881
Davidoff F.
Between the lines: Navigating the uncharted territory of industry-sponsored research: A former medical journal editor describes how and why staff changed their policy on disclosing conflicts of interest.
Health Affairs 2002 Mar-Apr;21(2):235-242
HSL2887
Cocconi G.
Independent clinical trials: a commentary.
Tumori 2002 Mar-Apr;88(2):85-8
Link to source with long URL
HSL2896
Brody H.
A matter of influence: Changing times call for changing policies on the prescence of drug company reps in residency programs
Health Affairs (Millwood). 2002 Mar-Apr;21(2):232-234
http://www.healthaffairs.org/freecontent/s28.htm
HSL7588
de Laat E, Windmeijer F, Douven R
How does pharmaceutical marketing influence doctors' prescribing behaviour?
2002 Mar
http://www.cpb.nl/nl/news/2002_11.html
HSL8389
Newton GD, Benninghoff AJ, Pray WS, Popovich NG.
New OTC drugs and devices 2001: a selective review.
J Am Pharm Assoc (Wash) 2002 Mar-Apr;42(2):267-77
HSL1972
Timmerman L.
Prescription plan becomes a racial issue
Seattle Times business reporter 2002 Feb 27
HSL1973
Johnson E.
Direct-to-consumer advertising
2002 Feb 27
HSL1974
Excepts from advertisements for mobile sales information systems from AvantGo
2002 Feb 27
HSL1970
FDA hits Elan, Pharmacia and Roche on ad practices
FDA news Daily Bulletin 2002 Feb 26
HSL1969
Pallarito K.
Vermont bill would impose fees on drug detailers
Reuters Health 2002 Feb 25
HSL1968
Ross B, Scott DW.
Do Drug Company Perks Influence Doctors? How Pharmaceutical Companies Use Enticement to ‘Educate’ Physicians
ABC News USA 2002 Feb 21
http://abcnews.go.com/Primetime/story?id=132141&page=1
HSL6146
Shann F.
Research in developing countries.
N Engl J Med 2002 Feb 21;346(8):627-8
HSL2156
Glazer JL.
Pharmaceutical representatives and resident physicians.
JAMA 2002 Feb 20;287(7):844
http://jama.ama-assn.org/cgi/content/full/287/7/844
HSL2265
Shuchman M.
The Olivieri dispute: no end in sight?
CMAJ 2002 Feb 19;166(4):487
Link to source with long URL
HSL2872
Gibson E, Baylis F, Lewis S.
Dances with the pharmaceutical industry.
CMAJ 2002 Feb 19;166(4):448-50
http://www.cmaj.ca/cgi/pmidlookup?view=long&pmid=11873922
HSL3097
Questions of interest
Canadian Medical Association Journal 2002 Feb 19;166(4):413
HSL1484
Wolfe SM.
Direct-to-consumer advertising--education or emotion promotion?
N Engl J Med 2002 Feb 14;346(7):524-6
http://content.nejm.org/cgi/content/extract/346/7/524
HSL1965
Drug companies are increasingly targeting patients
Associated Press 2002 Feb 14
HSL1967
Connolly C.
Drug Marketers Focus on Doctors: Consumer Ads Up -- but Still Secondary
Washington Post 2002 Feb 14
HSL2862
Holmer AF.
Direct-to-consumer advertising--strengthening our health care system.
N Engl J Med 2002 Feb 14;346(7):526-8
http://content.nejm.org/cgi/content/extract/346/7/526
HSL2878
Drazen JM.
The consumer and the learned intermediary in health care.
N Engl J Med 2002 Feb 14;346(7):523-4
http://content.nejm.org/cgi/content/full/346/7/523
HSL1964
Heinzl J.
Drug makers said to skirt Canadian restrictions on ads
Globe and Mail 2002 Feb 12
HSL1966
Neurontin (GABAPENTIN)--The Illegal Corporate Creation of a Blockbuster Drug
New York Times 2002 Feb 12
HSL1963
Spencer C.
Everyone gets to know about prescriptions -- except the patient
The Ottawa Citizen 2002 Feb 11
HSL1962
HAI DTCA statement
2002 Feb 10
HSL1960
Boseley S.
Scandal of scientists who take money for papers ghostwritten by drug companies: Doctors named as authors may not have seen raw data
The Guardian 2002 Feb 7
HSL1961
Boseley. S
'It said the drug was the best thing since sliced bread. I don't think it is'.
The Guardian. 2002 Feb 7
HSL1959
Stolberg S.
Study Says Clinical Guides Often Hide Ties of Doctors
New York Times 2002 Feb 6
HSL1958
Direct-to-Consumer Advertising of Pharmaceuticals
2002 Feb 5
HSL2616
Komesaroff PA, Kerridge IH.
Ethical issues concerning the relationships between medical practitioners and the pharmaceutical industry
Med J Aust 2002 Feb 4;176(3):118-21
Link to source with long URL
HSL1956
Mansfield P, Evans A.
Costs are important but it's medicines that save lives
Australian Financial Review 2002 Feb 2
HSL1957
Picard A.
Patients requesting advertised drugs
GLOBE AND MAIL 2002 Feb 2
HSL8392
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, Evans RG, Pan R, Marion SA.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey.
BMJ 2002 Feb 2;324(7332):278-9
http://www.bmj.com/cgi/content/full/324/7332/278
HSL5828
Barclay S, Todd C, Finlay I, Grande G, Wyatt P.
Not another questionnaire! Maximizing the response rate, predicting non-response and assessing non-response bias in postal questionnaire studies of GPs.
Fam Pract 2002 Feb 01;19(1):105-11
http://fampra.oxfordjournals.org/cgi/content/full/19/1/105
HSL1952
Jack I.
Majority wants drug ads legalized, poll shows
Financial Post: Canada 2002 Feb 1
HSL1955
68% of Canadians Support Direct to Consumer Advertising for Prescription Medications
Ipsos-Reid 2002 Feb 1
HSL4151
Mintzes B, Barer ML, Kazanjian A, Bassett K, Evans RG, Morgan S.
An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume I: Executive Summary.
: Centre for Health Services and Policy Research.; 2002 Feb 01Date uncertain
http://www.chspr.ubc.ca/hpru/pdf/dtca-v1-execsum.pdf
HSL2515
Mintzes , B. et al.
An assessment of the health system impacts of direct- to-consumer advertising of prescription medicines (DTCA)
Vancouver: Centre for Health Services and Policy research, The University of British Columbia; 2002 Feb
http://www.chspr.ubc.ca/hpru/pdf/dtca-v1-execsum.pdf
HSL1951
RiviÈre P.
Drug deals in Europe
Le Monde diplomatique 2002 Feb
HSL1975
Sandvik H.
Norwegian GPs Protest Withdrawal of Cheap Antihypertensives
Wonca News 2002 Feb
HSL2260
Studin I.
Reframing the pharmaceutical manufacturer/health plan relationship in managed care.
Manag Care 2002 Feb;11(2):46,
Link to source with long URL
HSL2868
Haugh R, Thrall TH, Scalise D.
Prescription for concern.
Hosp Health Netw 2002 Feb;76(2):44-9
Link to source with long URL
HSL2903
Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb;2(1):6-11
Link to source with long URL
HSL1948
This is your school on drugs
2002 Jan 31
HSL1949
Julie ROVNER.
Generic Drugs Could Cut Cost of Medicare Benefit
2002 Jan 31
HSL1950
Rovner J.
Generic Drugs Could Cut Cost of Medicare Benefit
2002 Jan 31
HSL5008
Website targets DTC ads.
PMLive.com 2002 Jan 31
http://www.pmlive.com/archive.cfm?&ArticleID=4380&back=-1
HSL1947
Harris G.
Merck will be spinning off Merck-Medco.
Wall Street Journal 2002 Jan 29
HSL1944
Zwillicht .
Congress to Seek $300 Billion for Medicare Benefit
Reuters Health 2002 Jan 28
HSL1946
Page S.
Drug ads: Saving lives, or selling snake oil?
The Ottawa Citizen 2002 Jan 28
HSL2253
Thomas PS, Tan KS, Yates DH.
Sponsorship, authorship, and accountability.
Lancet 2002 Jan 26;359(9303):351
http://linkinghub.elsevier.com/retrieve/pii/S0140673602075062
HSL2301
Peddicord D; Covance Inc; ICON Clinical Research; Inveresk Research Group; Kendle International, Inc; PAREXEL Internatinal Corporation; PPD Development; Quintiles Transnational Corporation.
Sponsorship, authorship, and accountability.
Lancet 2002 Jan 26;359(9303):350
http://linkinghub.elsevier.com/retrieve/pii/S0140673602075037
HSL7585
Di GIOVANNA.
Sponsorship, authorship, and accountability (3rd of 5 letters)
The Lancet 2002 Jan 26;359(350-351)
HSL7586
Kalman C.
Sponsorship, authorship, and accountability (5th of 5 letters)
The Lancet 2002 Jan 26;359(351-352)
HSL7587
Stonier P, Wells F.
Sponsorship, authorship, and accountability (2nd of 5 letters)
The Lancet 2002 Jan 26;359(350)
HSL1942
Freudenheim M.
Many H.M.O.'s for the Elderly Make Deep Cuts in Drug Aid
New York Times 2002 Jan 25
HSL2293
Reidenberg MM.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24;346(4):290-2
http://content.nejm.org/cgi/content/extract/346/4/290
HSL7579
Holmer AF.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24;346(4):290-2
HSL7580
International COMMITTEE.
Sponsorship, authorship, and accountability (7th of 7 letters)
New England Journal of Medicine 2002 Jan 24;364(4):291-292
HSL7581
Landow L.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24;346(4):290-2
HSL7582
Loder E.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24;346(4):290-2
HSL7583
Peddicord D.
Sponsorship, authorship, and accountability (5th of 7 letters)
New England Journal of Medicine 2002 Jan 24;346(4):291
HSL7584
Relman AS.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24;346(4):290-2
HSL1940
Fraser M.
Drugs, ads and the 'direct' debate: Broadcasters want ability to peddle brand name drugs
Financial Post 2002 Jan 21
HSL1939
Brubaker B.
Drug Firms Still Lavish Pricey Gifts On Doctors Ethics Debated As Freebies Flow
Washington Post 2002 Jan 19
HSL1937
Corbey D
Patient doesn’t benefit from direct-to-consumer advertising
Opinion page NRC Handelsblad 2002 Jan 17
HSL1936
US Docs Opt for Pricey Drugs for Urinary Infection
Reuters Health 2002 Jan 14
HSL1935
Barnes S.
Not a Generic Medicaid Director
New York Times 2002 Jan 13
HSL1934
Debate opens on direct-to-consumer drug promotion in Europe
Press Release: Brussels 2002 Jan 11
HSL1849
The Bureau of National Affairs, Inc
Bush Signs Pediatric Incentive Bill Extending Exclusivity Provision Until 2007
2002 Jan 9
HSL1850
Bush Signs Pediatric Incentive Bill Extending Exclusivity Provision Until 2007
BNA Health Daily Report. 2002 Jan 9
HSL1847
Petersen M.
Pfizer's Chief Is Subpoenaed in an Inquiry on Drug Pricing
New York Times 2002 Jan 8
HSL1848
FTC Questions Patent Listings on Brand-Name Prescription Drugs
Kaiser Daily Health Policy Report 2002 Jan 8
HSL1846
Davis A.
'Postmarketing' by Makers of Alzheimer's Pill Raises Questions About the Uses of Research
THE WALL STREET JOURNAL 2002 Jan 7
HSL1845
Gold R.
Federal Judge Lets Stand Florida Law Seeking Rebates From Drug Makers
THE WALL STREET JOURNAL 2002 Jan 3
HSL2312
Morin K, Rakatansky H, Riddick FA Jr, Morse LJ, O'Bannon JM 3rd, Goldrich MS, Ray P, Weiss M, Sade RM, Spillman MA.
Managing conflicts of interest in the conduct of clinical trials.
JAMA 2002 Jan 2;287(1):78-84
http://jama.ama-assn.org/cgi/content/full/287/1/78
HSL1483
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA.
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
Am J Health Syst Pharm 2002 Jan 1;59(1):42-9
http://www.ajhp.org/cgi/reprint/59/1/42
HSL8430
Young D.
Studies show drug ads influence prescription decisions, drug costs.
Am J Health Syst Pharm 2002 Jan 1;59(1):14,
http://www.ajhp.org/cgi/reprint/59/1/14
HSL8431
Young D.
States form coalitions to leverage lower prescription drug prices.
Am J Health Syst Pharm 2002 Jan 1;59(1):20-1
http://www.ajhp.org/cgi/pmidlookup?view=reprint&pmid=11813461
HSL8448
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA.
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
Am J Health Syst Pharm 2002 Jan 1;59(1):42-9
http://www.ajhp.org/cgi/reprint/59/1/42
HSL1843
National Health.
Direct-To-Consumer Prescription Drug Advertising
2002 Jan
HSL1844
Norris P.
Talking the Talk
Prescriber Update 2002 Jan
HSL2157
Wolfe SM.
The destruction of medicine by market forces: teaching acquiescence or resistance and change?
Acad Med 2002 Jan;77(1):5-7
http://www.academicmedicine.org/cgi/content/full/77/1/5
HSL2259
Sumpradit N, Fors SW, McCormick L.
Consumers' attitudes and behavior toward prescription drug advertising.
Am J Health Behav 2002 Jan-Feb;26(1):68-75
Link to source with long URL
HSL2264
Simmer WS.
Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Manag Care Interface 2002 Jan;15(1):90-2
Link to source with long URL
HSL2308
National Health Council 2002 Jan
www.nationalhealthcouncil.org/advocacy/DTC_paper.pdf
HSL2458
Shakir SA, Layton D.
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Drug Saf 2002;25(6):467-71
Nil
HSL2511
Families USA.
Profiting from pain: where prescription drug dollars go. Families USA Publication No. 02- 105.
Washington, DC: Families USA; 2002 07
http://www.familiesusa.org/site/DocServer/PPreport.pdf?docID=249
HSL2512
WHO Department of Essential Drugs & Medicines Policy
Drug Promotion Database
: WHO Department of Essential Drugs & Medicines Policy; 2002
http://www.drugpromo.info/
HSL2621
Kind M.
[Physicians--victims or promoters of corruption?].
Wien Med Wochenschr. 2002;152(9-10):249-52
Link to source with long URL
HSL111
Saver JL, Kidwell CS, Starkman S.
Commentary: thrombolysis in stroke: it works!
BMJ 2002;324:727-729
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723
HSL112
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM.
Promotion of prescription drugs to consumers
N Engl J Med 2002;346:498-505
http://content.nejm.org/cgi/content/abstract/346/7/498
HSL113
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002;324:278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278
HSL115
Coyle SL.
Physician-industry relations. Part 2: organizational issues
Ann Intern Med 2002;136:403-406
http://www.annals.org/cgi/reprint/136/5/403.pdf
HSL116
Coyle SL.
Physician-industry relations. Part 1: individual physicians
Ann Intern Med 2002;136:396-401
http://www.annals.org/cgi/reprint/136/5/396.pdf
HSL117
Choudhry NK, Stelfox HT, Detsky AS
Relationships between authors of clinical practice guidelines and the pharmaceutical industry
JAMA 2002;287:612-617
http://jama.ama-assn.org/cgi/content/full/287/5/612
HSL2497
De Latt, Windmeijer F, Douven R.
How does pharmaceutical marketing influence doctors' prescribing behaviour?
The Hague: CPB Netherlands Bureau for Economic Policy Analysis; 2002
http://www.cpb.nl/nl/pub/bijzonder/38
HSL2569
Lyles A.
Direct marketing of pharmaceuticals to consumers.
Annu Rev Public Health 2002;23:73-91
Link to source with long URL
HSL2611
Lefebvre T.
[Archeology of the radio pharmaceutical advertisement].
Rev Hist Pharm (Paris). 2002;50(336):647-64
Link to source with long URL
HSL2376
Menon AM, Deshpande AD, Perri M 3rd, Zinkhan GM.
Trust in online prescription drug information among internet users: the impact on information search behavior after exposure to direct-to-consumer advertising.
Health Mark Q 2002;20(1):17-35
Link to source with long URL
HSL2244
Warlow C.
Commentary: who pays the guideline writers
BMJ 2002;324:726-727
HSL2246
Vlasov VV.
[Emerging problems of medical ethics in Russia: medical practice and research]
Kardiologiia. 2002;42(5):81-4. 2002;42(5):81-4
Link to source with long URL
HSL2302
Pavenik N.
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Rand J Econ 2002 Aut;33(3):469-87
Link to source with long URL
HSL2307
Neubauer A.
[Consequences of the German anticorruption law for sponsorship at university hospitals].
Wien Med Wochenschr 2002;152(9-10):246-8
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1563-258X.2002.02038.x
HSL2622
Kemper DW, Mettler M.
A consumer-empowered response to direct-to-consumer advertising of prescription drugs.
Manag Care Q 2002 Spring;10(2):52-4
Link to source with long URL
HSL2853
Jedrey CM, Chaurette KA, Winn LB.
Pharmaceutical company-sponsored disease management programs.
Manag Care Q 2002 Win;10(1):56-60
Link to source with long URL
HSL2855
Isidor JM, Kaltman SP.
Fast track to disaster? Considerations raised by the current recruitment techniques for clinical research subjects
J Biolaw Bus 2002;5(3):46-7
Link to source with long URL
HSL2857
Health Action International.
The Erice Statement on drug advertising to consumers
2002
http://www.haiweb.org/campaign/DTCA/EriceStatement2002.doc
HSL2860
Hosch H.
[Research support and the pharmaceutical industry in Germany.]
Wien Med Wochenschr. 2002;152(9-10):238-40
Link to source with long URL
HSL2861
Hoogenberg K, van der Tuin J.
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Ned Tijdschr Geneeskd. 2002 November 2;146(44):2099-100
Link to source with long URL
HSL2864
Hochhauser M.
Which prescription for the illegible and unreadable DTC (direct-to-consumer) brief summary--major surgery or euthanasia?
Manag Care Q 2002 Sum;10(3):6-10
Link to source with long URL
HSL2865
Hirsch LJ.
Conflicts of interest in drug development: the practices of Merck & Co., Inc
Sci Eng Ethics 2002 July;8(3):429-42
Link to source with long URL
HSL2867
Healy DI.
Conflicting interests in Toronto: anatomy of a controversy at the interface of academia and industry.
Perspect Biol Med 2002 Spr;45(2):250-63
Link to source with long URL
HSL2869
Graber MA, Weckmann M.
Pharmaceutical company internet sites as sources of information about antidepressant medications.
CNS Drugs 2002;16(6):419-23
Link to source with long URL
HSL2870
Golden GA, Parochka JN, Overstreet KM.
Medical education and communication companies: an updated in-depth profile.
J Contin Educ Health Prof 2002 Win;22(1):55-62
Link to source with long URL
HSL2874
Findlay S.
Do ads really drive pharmaceutical sales? The true effects of DTC advertising remain a mystery
Mark Health Serv. 2002 Spr;22(1):20-25
HSL2894
Carter T.
What can Johnson & Johnson do to remain a giant in the health care industry?
J Hosp Mark Public Relations 2002;14(1):93-103
Link to source with long URL
HSL2895
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20
Link to source with long URL
HSL2900
Bojunga G.
[Is research in Germany up for sale?
Results of a study of Transparency International Germany]Wien Med Wochenschr 2002;152(9-10):244-5
Link to source with long URL
HSL2901
Bode UH, Geisler EP.
[Medical ethics as output of economically motivated industrial objectives].
Wien Med Wochenschr. 2002;152(13-14):309-12
Link to source with long URL
HSL2905
Baird PA.
Identification of genetic susceptibility to common diseases: the case for regulation.
Perspect Biol Med 2002 Fal;45(4):516-28
Link to source with long URL
HSL2907
Allen AJ, Michelson D.
Drug development process for a product with a primary pediatric indication.
J Clin Psychiatry 2002;63:44-9
http://www.psychiatrist.com/pcc/pccpdf/v04s04/v63s1207.pdf
HSL4161
Innvaer S, Vist G, Trommald M, Oxman A.
Health policy-makers’ perceptions of their use of evidence: a systematic review.
J Health Ser Res Policy. 2002;4:239–244
HSL4165
Coney S.
Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand.
J Public Policy Market. 2002;21:213–223.
HSL4285
Is Yasmin a "truly different" pill?
Drug Ther Bull 2002;40(8):57-9
Link to source with long URL
HSL5002
O'Keefe DJ.
Persuasion: Theory & Research 2nd Edn.
Thousand Oaks: Sage; 2002
HSL5069
Kamm MA.
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Eur J Surg Suppl 2002(587):10-5
HSL5320
Ghosh S.
Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Fla J Int Law 2002 Spr;14(2):217-60
HSL5321
Nagan WP.
International intellectual property, access to health care, and human rights: South Africa v. United States.
Fla J Int Law 2002 Spr;14(2):155-91
HSL6218
Nakamura L.
Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. [Review of: Wilson, R. Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. University Park, Pa.: Penn State Pr., 2000]
J South Hist. 2002;68(3):677-8
HSL8083
Palumbo FB, Mullins CD.
The Development of Direct-to-Consumer Prescription Drug Advertising Regulation
Food and Drug Law Journal 2002;57(3):423-443
Link to source with long URL
HSL8251
Lexchin J.
Should doctors be prescribing new drugs?
International Journal of Risk and Safety in Medicine 2002;15(3-4):213-222
HSL8254
Lawrence LW.
A study of consumer recall of prescription medication advertisements
Journal of Pharmaceutical Marketing and Management 2002;15(1):52-58
HSL8255
Spiller LD, Wymer WW.
Physicians' responses to marketing strategies of pharmaceutical companies
Journal of Pharmaceutical Marketing and Management 2002;15(1):15-30
HSL8267
Mossialos E, Mrazek MF.
Data needed for developing and monitoring policies
International Journal of Risk and Safety in Medicine 2002;15(1-2):15-27
HSL8279
Vivian JC.
Federal limits on gifts from pharmaceutical companies
US Pharmacist 2002;27(11):96-98,101
HSL8281
Adcock H.
Pharmageddon: is it too late to tackle growing resistance to anti-infectives?
Pharmaceutical Journal 2002;269(7221):599-600
HSL8283
Goeschl T.
Stakes in the evolutionary race: The economic value of plants for medicinal applications
Journal of Herbs Spices and Medicinal Plants 2002;9(4):373-388
HSL8284
Koch YD, Ernst ME, Kelly MW.
Patient perceptions about drug advertising and prescription-to-nonprescription switches
American Journal of Health System Pharmacy 2002;59(16):1568
HSL8286
Drife J.
Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
Drug Saf 2002;25(13):893-902
HSL8288
Vidotti CC, Pereira DM, Marin NJ.
Drug nomenclature in Brazil: The official project "Harmonization of drug and excipients nomenclature for use in medicines"
International Pharmaceutical Federation World Congress 2002;62(147)
HSL8290
Bessell TL, Silagy CA, Anderson JN, Hiller JE, Sansom LN.
Can we regulate e-pharmacies?
International Pharmaceutical Federation World Congress 2002;62(68)
HSL8292
Subramaniam V, Schmid J.
Patient safety and regulatory initiatives through drug quality monitoring: Perspectives from the Food and Drug Administration
International Pharmaceutical Federation World Congress 2002;62(9)
HSL8294
Griffenhagen G.
150 years of American pharmacy
International Pharmaceutical Federation World Congress 2002;62(153)
HSL8296
Wogalter MS, Smith-jacksontl , Mills BJ, Paine CS.
The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference
Drug Information Journal 2002;36(3):693-705
HSL8298
Kiene B, Braun N, Freund M, Kliegl T.
Public advertising for prescription medicine
Deutsche Apotheker Zeitung 2002;142(18):59-63
HSL8300
Sellers LJ.
Lilly marketers cross the line
Pharmaceutical Executive 2002;22(9):20
HSL8304
Kiene B, Braun N, Freund M, Kliegel T.
Public advertising for prescription medication. Part 2. Different interests and solutions
Deutsche Apotheker Zeitung 2002;142(19):47-50,55-57
HSL8305
Southern WA.
Sources of drug market data [1953].
Pharm Hist 2002;44(2):77-82
HSL8307
Houlton S.
Drug info war heats up
Pharmaceutical Executive 2002;22(8):30
HSL8360
Alonso J.
CRM - The 'ecosystem' difference
Pharmaceutical Executive 2002;22(8):44,46,48,50,52
HSL8362
O'Hara P.
Policing CRM sampling
Pharmaceutical Executive 2002;22(8):56,58,60,62-63,66
HSL8363
Wechsler J.
House adopts Medicare rx benefit
Pharmaceutical Executive 2002;22(8):26,28
HSL8364
Buckley B.
Center saves millions via indigent care plans
Pharmacy Practice News 2002;29(7):13, 51
HSL8365
Egler M, Geursen R.
Reference pricing: When hope triumphes over reality
Drugs Made in Germany 2002;45(2):35-38,40-42
HSL8366
Koo M, Krass I, Aslani P.
Consumer opinions on medicines information and factors affecting its use - an Australian experience
International Journal of Pharmacy Practice 2002;10(2):107-114
HSL8367
Drugs in 2001 - A number of ruses unveiled
Prescrire International 2002;11(58):58-60
HSL8368
Boland KA, Kennedy AG, Possidente CJ.
Development of an annual program to discuss innovative pharmacy practices in Vermont
ASHP Midyear Clinical Meeting 2002
HSL8369
Peters BN, Boster EA, Kroskie CA, Morvay SI, Zaucha JA.
Redesign of a pharmacy internship program
ASHP Midyear Clinical Meeting 2002
HSL8370
Del PAGGIO.
Evaluation of atypical antipsychotic medication assistance programs in a county mental health system
ASHP Midyear Clinical Meeting 2002
HSL8371
Daberko JD, Bays AM, Kier KL.
Evaluating web-based direct-to-consumer advertising
ASHP Midyear Clinical Meeting 2002
HSL8372
Rosier RA, Phillips RE, Elam JW.
Medication assistance outpatient program; providing access to free or low cost pharmaceuticals.
ASHP Midyear Clinical Meeting 2002
HSL8373
Aggarwal K, Cowley EP.
Beyond approved labeling: The USPDI medication information development process.
ASHP Midyear Clinical Meeting 2002
HSL8374
Top 10 drugs of 2001
Pharmacy Times 2002;68(4):10,12,15
HSL8375
Smith NV, Ramseyer KE.
Taking the package insert into the electronic age
Drug Information Journal 2002;36(2):429-434
HSL8376
Kaupp GS, Lynch SB.
To regain control of their drug costs, health plans must understand the road they've traveled
Drug Benefit Trends 2002;14(4):49-50
HSL8377
Advertised prescription drugs are the hot sellers
Drug Benefit Trends 2002;14(4):4
HSL8378
Chumney EC, Simpson KN.
The emerging role of the consumer in pharmaceutical pricing decisions
Disease Management and Health Outcomes 2002;10(4):229-232
HSL8380
Schobben AF, Rademaker CM.
Awakening attention for a particular target group. Drug registrations for children
Pharmaceutisch Weekblad 2002;137(18):651-654
HSL8381
Milne CP.
The single controlled trial: Industry survey indicates that implementation is still a work in progress
Drug Information Journal 2002;36(2):291-302
HSL8382
Saunders B, Farine A, Kellerman J.
Caught in the crosshairs - Pharmaceutical pricing and sales & marketing practices
Pharmaceutical Executive 2002;22(4):50,52,54,56,58
HSL8383
Wechsler J.
Congress expands drug safety surveillance as part of bioterrorism bill
Formulary 2002;37(7):368-369
HSL8384
Shalo S.
The cyber six: ePharma's hot growth spots
Pharmaceutical Executive 2002;22(1):72-74,76,78
HSL8385
Nozar RA.
Education and promotion of generics might put the brakes on pharm costs
Managed Healthcare Executive 2002;12(2):36, 38
HSL8386
Gebhart F.
Still growing - Steady, not stellar, growth marked the pharmaceutical market last year
Drug Topics 2002;146(6):25-26,28,30
HSL8387
Wechsler J.
Price push forces plans to shift costs to consumers - MCOs implement multi-tier benefit to slow drug-spending growth, but future fiscal controls could limit access
Managed Healthcare Executive 2002;12(1):32-33
HSL8390
Rybicki AL.
Pharmacists fill a prescription for good health
Michigan Pharmacist 2002;40(1):38-39
HSL8391
Gebhart F.
Pharmacists welcome vouchers in place of drug samples
Drug Topics 2002;146(2):25-26
HSL8397
Thornton RA, Hamilton S, Helmeczi AW.
Effective utilization of manufacturer's indigent medication reimbursement programs and patient financial screening to reduce financial losses in an ambulatory pharmacy setting.
ASHP Summer Meeting 2002;59:36
HSL10907
Mongin Bulewski C.
Drug Discovery Technology 2002: Keynote lectures: 4-9 August 2002, Boston, MA, USA
IDrugs 2002;5(9):900-901
HSL11029
Dexmethylphenidate - Novartis/Celgene: Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride
Drugs in R and D 2002;3(4):279-282
HSL11096
Iloprost - A small benefit in severe Raynaud's phenomenon
Prescrire International 2002;11(58):63
HSL11135
Frasca V, Paladini L, Balestrieri A.
Prescription information leaflets: An expression of pharmaceutical care
Giornale Italiano di Farmacia Clinica 2002;16(4):207-209
HSL11147
Ou YJ.
A survey of pharmacists' recommendation in a unit dose drug distribution system
Chinese Pharmaceutical Journal 2002;54(6):449-455
HSL11189
Oreskovic S.
Pharmacoeconomics - Concepts, methods and controverses
Medicus 2002;11(1):27-36
HSL11191
De Joncheere K, Rietveld AH, Huttin C.
Experiences with generics
International Journal of Risk and Safety in Medicine 2002;15(1-2):101-109
HSL11201
McCloskey A.
The high price of prescription drugs and its impact on the elderly.
Care Manag J 2002 Spr;3(3):143-53
HSL11202
Kellogg FR.
Editorial
Care Management Journals 2002;3(3):112
HSL11203
Brown K.
The medication merry-go-round
Science 2002;299(5613):1646-1649
HSL11211
Hilli R, Groop T.
Generic Substitution - The proposed procedure for the presciption of pharmaceuticals in Finland
EPC--European Pharmaceutical Contractor 2002:101-103
HSL11212
Schulman D, Wallis D, Hunsperger H.
Prescription drug Co-Promotion: 21st century dealmaking
EPC European Pharmaceutical Contractor 2002:26-28
HSL11213
Coppin B.
A call to regulate the online sale of prescription drugs
EPC European Pharmaceutical Contractor 2002:18-20
HSL11287
Tacco F, Taggiasco N, Broissand C.
Quality assurance in hospital pharmacies: Dispensation of thalidomide
Pharmacien Hospitalier 2002;37(151):219-226
HSL11295
Breggin PR.
Fluvoxamine as a cause of stimulation, mania, and aggression: A critical analysis of the FDA-approved label
Ethical Human Sciences and Services 2002;4(3):211-227
HSL11300
Drachenberg KJ, Proll S, Urban E, Woroniecki SR.
Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: A post-marketing surveillance study
International Review of Allergology and Clinical Immunology. 2002;8(4):219-223
HSL11305
Spinosi P, Ciampoli R, Turchetti M.
Did any change occurr in the NSAIDs prescription following the marketing of selective COX-2 inhibitors?
Giornale Italiano di Farmacia Clinica 2002;16(3):138-142
HSL11306
Horn SD.
Unintended consequences of restricting drug access
Drug Benefit Trends 2002;14
HSL11313
Krymchantowski AV, Irikura S, Barbosa JS, Lysia R, Tavares C, Rocha N, Moreira PF.
Headache medications in drugstores of Brazil. Profiles of orientation, recommendation and sale carried out by unskilled employees with inadequate approaches
Revista Brasileira de Medicina 2002;59(10-11):705-710
HSL11314
Mason RG, Donaldson D.
Lessons to be learned: A case study approach Chinese herbal nephropathy and urothelial malignancy
Journal of The Royal Society for the Promotion of Health 2002;122(4):266-267
HSL11317
Gallagher RM.
Methadone and spinal stimulation: Old wine in new bottles
Pain Medicine 2002;3(4):293
Link to source with long URL
HSL11318
Kanemori DS.
Future packaging image
American Pharmaceutical Outsourcing 2002;3(4):18-22
HSL11320
Something for everyone - Patients, health care professionals and industry
Pharmaceutical Journal 2002;269(7228):861
HSL11322
Noferi JF, Arling ER, Dillon RL.
Counterfeit drugs: A new paradigm for security
American Pharmaceutical Review 2002;5(4):37
HSL11323
Dwyer P.
Drug therapy and legal liability
Australian Journal of Forensic Sciences 2002;34(2):45-46
HSL11324
Striking-off for Viagra sale to journalist
Pharmaceutical Journal 2002;269(7227):829
HSL11327
Zeidler H, Kaltwasser JP, Leonard JP, Kohlmann T, Sigmund R, Degner F, Hettich M.
Prescription and tolerability of meloxicam in day-to-day practice: Postmarketing observational cohort study of 13,307 patients in germany
Journal of Clinical Rheumatology 2002;8(6):305-315
HSL11328
Patient packs need attention too
Pharmaceutical Journal 2002;269(7226):766
HSL11329
Wechsler J.
Major changes ahead for FDA
Pharmaceutical Technology Europe 2002;14(11):17-20
HSL11330
Albedo A.
Battle commences on the future of EU drugs
Pharmaceutical Technology Europe 2002;14(11):11-13
HSL11333
Sodium oxybate/GHB approved for cataplexy
WHO Drug Information 2002;16(2):136
HSL11334
Alosetron hydrochloride: Restricted marketing
WHO Drug Information 2002;16(2):135
HSL11335
MacKay DKJ.
Prescribing cascade for non-food-producing species, and changes relating to cushing's disease [1]
Veterinary Record 2002;151(21):643
HSL11336
Pet medicines 'resource pack' for pharmacists
Veterinary Record 2002;151(21):620
HSL11337
Abraham J.
Making regulation responsive to commercial interests: Streamlining drug industry watchdogs
British Medical Journal 2002;325(7373):1164-1167
HSL11338
Barnes J.
Herbal therapeutics: (7) Colds
Pharmaceutical Journal 2002;269(7224):716
HSL11339
OTC availability shout not be endorsed yet [1]
Pharmaceutical Journal 2002;269(7224):711
HSL11340
Cost and compliance affect statin use
Pharmaceutical Journal 2002;269(7224):706
HSL11341
Dispensing glucosamine
Pharmaceutical Journal 2002;269(7224):705
HSL11492
Curth L.
The commercialisation of medicine in the popular press: English almanacs 1640-1700.
Seventeenth Century 2002;17(1):48-69
HSL12601
Goldman CR, Cutler DL.
Pharmaceutical industry support of psychiatric research and education: Ethical issues and proposed remedies.
Backlar P, Cutler DL. Ethics in community mental health care: Commonplace concerns. New York: Kluwer Academic/Plenum Publishers; 2002
HSL14024
Lexchin J, Mintzes B.
Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No
Journal of Public Policy and Marketing 2002;21(2):194-201
http://www.marketingpower.com/content18627.php
HSL14038
Pecotich A, Ward SP, Song Y.
Just a Spoonful of Sugar: Patent Brand Name Effects on the Antidepressant Prescription Habits of Psychiatrists and General Practitioners
Cadeaux J, Pecotich A, Eds . Macromarketing in the Asia Pacific Century: The Proceedings of the 27th Annual Macromarketing Conference Sydney: University of New South Wales; 2002
HSL14105
Schubert F.
Health technology assessment. The pharmaceutical industry perspective
Int J Technol Assess Health Care. 2002 Spring;18(2):184-91
http://www.ncbi.nlm.nih.gov/pubmed/12053418
HSL8379
Tieman J.
Drug-altered states - As pharmaceutical spending continues to soar, state legislatures are taking bold steps to rein in their costs
Modern Healthcare 2002;32(17):28-31
HSL11093
Selegiline: a second look.
Six years later: too risky in Parkinson's disease 2002;11(60):108-111
HSL13057
Quintaneiro T.
[The Brazilian pharmaceutical market and the North American war effort].
Estud Hist. 2002(29):141-64